Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide + RT vs RT in Grade III Gliomas Without 1p/19q Codeletion
NCT01534845Phase 2Unknown
- Start
- Mar 2012
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in anaplastic glioma (2 arms). Primary endpoint: 2-year Progression-Free Survival. Status: unknown.
02
Drugs
temozolomide
03
Conditions
anaplastic glioma
Beyond the preview
Go deeper on NCT01534845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01534845.